Manassantin A inhibits cAMP-induced melanin production by down-regulating the gene expressions of MITF and tyrosinase in melanocytes.

College of Pharmacy, Yeungnam University, Kyungsan, Korea College of Pharmacy, Chungbuk National University, Cheongju, Korea College of Pharmacy, Chungnam National University, Daejeon, Korea.
Experimental Dermatology (Impact Factor: 3.58). 05/2011; 20(9):761-3. DOI: 10.1111/j.1600-0625.2011.01296.x
Source: PubMed

ABSTRACT Microphthalmia-associated transcription factor (MITF) is inducible in response to cAMP through the cAMP-responsive element-binding protein (CREB) and plays a pivotal role in the melanocyte-specific expression of tyrosinase or tyrosinase-related proteins (TRPs) for melanin biosynthesis. Manassantin A from Saururus chinensis inhibits cAMP-induced melanin production in B16 melanoma cells. Here, we focused on molecular basis of the antimelanogenic activity. Manassantin A consistently inhibited the cAMP elevator 3-isobutyl-1-methylxanthine (IBMX)- or dibutyryl cAMP-induced melanin production in B16 cells or in melan-a melanocytes by down-regulating the expression of tyrosinase or TRP1 gene. Moreover, manassantin A suppressed MITF induction through IBMX-activated CREB pathway, directly inhibiting the Ser-133 phosphorylation of CREB. However, manassantin A did not affect IBMX-increased cAMP levels in these cells but also other cAMP-dependent melanogenic pathways through post-translational modifications of MITF. This putative molecular mechanism of manassantin A in the inhibition of melanin production suggests its pharmacological potential in skin hyperpigmentation.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A3 adenosine receptor, A3AR, belongs to the Gi proteins coupled receptors. Activation of A3AR by its agonist, IB-MECA, decreases cAMP and was expected to reduce melanin level. Unexpectedly, B16 melanoma cells exposed to IB-MECA increased melanin levels in a dose-dependent manner. Human skin explants exposed to IB-MECA showed an increase in DOPA positive cells and in melanin deposition in keratinocytes. The agonist induced AKT phosphorylation, leading to a rapid translocation of the transcription factor MiTF towards the nucleus. DOPA oxidase activity and melanin levels induced by IB-MECA were further enhanced by PD98509, an inhibitor ERK signalling pathway. Our study shows that IB-MECA decreases cAMP while inducing melanogenesis. The proposed mechanism involves activation of PI3K/AKT signalling pathway by β/γ subunits of the G protein coupled to A3AR. The increase in melanin level in human skin explants suggests that IB-MECA may be a potential candidate to the treatment of hypopigmentation of skin.
    Experimental Dermatology 09/2012; · 3.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We investigated the in vitro effects of p-coumaric acid on melanogenesis. The melanin content in B16F1 cells stimulated with p-coumaric acid significantly decreased (68 % vs. control) through inhibition of tyrosinase enzyme activity assessed using both cell-free and cell-based assays (46 and 27 % compared with control, respectively). In addition, stimulating B16F1 cells with p-coumaric acid reduced cyclic adenosine monophosphate (cAMP)—responsive element-binding protein (CREB) protein phosphorylation (26 % vs. control), which in turn downregulated the expression of the microphthalmia-associated transcription factor (MITF) and its target gene tyrosinase (27 and 20 % vs. control, respectively). p-Coumaric acid has a hypopigmentation effect in melanocytes by both directly inhibiting tyrosinase enzyme activity and reducing CREB phosphorylation, which inhibits MITF and tyrosinase expression.
    European Food Research and Technology 235(6). · 1.39 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The dineolignan manassantin A from Saururaceae was recently identified as a hypoxia-inducible factor 1 (HIF-1) inhibitor, but its in-vivo anti-tumor effect has not been explored. We synthesized a series of manassantin A derivatives, and found that replacing the central tetrahydrofuran moiety with a cyclopentane ring yielded a compound (LXY6006) with increased HIF-1-inhibitory activity yet decreased stereochemically complexity amenable to a simplified synthesis scheme. LXY6006 inhibited HIF-1α nuclear accumulation induced by hypoxia, and inhibited cancer cell growth as a consequence of G2/M arrest. Oral administration of LXY6006 significantly inhibited growth of breast, lung, and pancreatic tumors implanted in nude mice. These results indicate that LXY6006 represents a novel class of agents targeting a broad range of human cancers.
    PLoS ONE 01/2014; 9(6):e99584. · 3.53 Impact Factor


1 Download